Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Efbemalenograstim Alfa→

Efbemalenograstim Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2200269-79-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Long-acting granulocyte colony-stimulating factor (G-CSF) analogpegylated leukocyte growth factor
Mechanism of action
Binds G-CSF receptors on haematopoietic progenitor cells and neutrophils, stimulating proliferation, differentiation and survival of neutrophil precursors and increasing circulating neutrophil counts.
Indications / reported uses
  • To decrease the incidence of infection, manifested as febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; not indicated for peripheral-blood stem-cell mobilisation

Sources: NLM DailyMed — RYZNEUTA (efbemalenograstim alfa-vuxw), label updated 19 May 2026 · FDA label — RYZNEUTA · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Long-acting granulocyte colony-stimulating factor (G-CSF) analog; pegylated leukocyte growth factor

Mechanism of action

Binds G-CSF receptors on haematopoietic progenitor cells and neutrophils, stimulating proliferation, differentiation and survival of neutrophil precursors and increasing circulating neutrophil counts.

General use cases

  • To decrease the incidence of infection, manifested as febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; not indicated for peripheral-blood stem-cell mobilisation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Efbemalenograstim Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Efbemalenograstim Alfa Permitted Daily Exposure (PDE) report (the Efbemalenograstim Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Efbemalenograstim Alfa Occupational Exposure Limit (OEL) report (the Efbemalenograstim Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.